Table 2.

Antibodies producing statistically different binding levels between the patient classes in both experiment sets

Healthy vs. cancerHealthy vs. benignCancer vs. benign
Higher in cancerPHigher in benignPHigher in cancerP
Anti-CRP (ab 2)<0.001, <0.001Anti-α-1-antitrypsin (ab 2)<0.001, <0.001Anti-PIVKA-II0.005, 0.031
Anti-PIVKA-II<0.001, <0.001Anti–serum amyloid A<0.001, <0.001Anti-CA15-30.024, 0.05
Anti-α-1-antitrypsin (ab 2)0.004, <0.001Anti-CRP (ab 2)<0.001, <0.001
Anti-IgA0.014, <0.001Anti–alkaline phosphatase0.006, 0.007
Anti-α-1-antitrypsin (ab 1)0.021, <0.001
Anti–cathepsin D0.009, 0.014
Anti–alkaline phosphatase0.007, 0.02
Lower in cancerPLower in benignPLower in cancerP
Antigelsolin<0.001, <0.001Antiplasminogen<0.001, 0.001Anti–serum amyloid A0.006, 0.002
Anti-TNFα<0.001, <0.001Anti-MPM2<0.001, 0.004
Anti-MPM20.003, 0.002Anti-M2-PK0.009, <0.001
Anti-IL-6 sR0.005, <0.001Anti-IL-6 sR0.011, 0.002
Anti-IL-8 (ab 1)0.003, 0.004Anti-IL-8 (ab 1)0.01, 0.002
Antitransferrin0.001, 0.006Anti-α-2 antiplasmin0.009, 0.005
Anti–troponin T0.016, 0.013Anti-PAI-10.012, 0.006
Antithioredoxin0.034, <0.001Anti-CA15-30.01, 0.012
Anti-α-2 antiplasmin0.028, 0.011Antigelsolin0.026, 0.001
Anti-IGF-I0.025, 0.045Anti-CA1250.02, 0.018
Anti-α-fetoprotein (ab 2)0.018, 0.029
Anti-CEA0.007, 0.043
Antitransferrin0.03, 0.023
Anti-CRP (ab 1)0.021, 0.036
Anti-TNFα0.049, 0.023
  • NOTE: The P values for both sets 1 and 2 are given, respectively, for the indicated comparisons. Abbreviations: TNFα, tumor necrosis factor α; PAI, plasminogen activator inhibitor; IGF, insulin-like growth factor.